Morschhauser F, et al. - In patients with relapsed/refractory (R/R) follicular lymphoma (FL), induction and maintenance with obinutuzumab (GA101; G) plus lenalidomide (LEN) showed favourable activity and tolerable safety in the phase 2 GALEN study and in this setting G plus atezolizumab (atezo) has also exhibited activity researchers presented primary effectiveness and safety data from a phase 1b/2 study assessing induction and maintenance with G-LEN-atezo in patients with R/R FL. For this investigation, all patients had received ≥1 prior anti-CD20-containing chemoimmunotherapy regimen. According to findings, the EOI CR rate for the G-LEN-atezo chemo-free regimen is comparable to the treatment options currently available in this indication and is higher than with historical controls with long-lasting activity. The overall safety and tolerability profile for the individual drugs and for G-LEN is consistent with the known profiles. The overall safety and tolerability profile is consistent with the known profiles for the individual drugs and for G-LEN.